Minimal change is sensitive, less specific to recovery: a diagnostic testing approach to interpretability.
暂无分享,去创建一个
Sheilah Hogg-Johnson | Dwayne van Eerd | S. Hogg-Johnson | D. Beaton | Gabrielle M van der Velde | K. Cullen | D. Van Eerd | C. Kennedy | Peter M. Smith | Dorcas E Beaton | Peter Smith | Gabrielle van der Velde | Kimberley Cullen | Carol A Kennedy
[1] D. Cook,et al. Health status, quality of life, and the individual. , 1994, JAMA.
[2] Ron D. Hays,et al. The Concept of Clinically Meaningful Difference in Health-Related Quality-of-Life Research , 2012, PharmacoEconomics.
[3] Ron D Hays,et al. Evaluating the Statistical Significance of Health-Related Quality-Of-Life Change in Individual Patients , 2005, Evaluation & the health professions.
[4] R. Fletcher,et al. Clinical Epidemiology: The Essentials , 1982 .
[5] G. Guyatt,et al. Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.
[6] T. Mayer,et al. Minimal Clinically Important Difference , 2010, Spine.
[7] C. Bombardier,et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement , 2004, Annals of the rheumatic diseases.
[8] C. Kelleher,et al. How much is enough and who says so? , 2004, BJOG : an international journal of obstetrics and gynaecology.
[9] A. Oza,et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W M Tierney,et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. , 1999, Medical care.
[11] D. Beaton,et al. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. , 2002, Current opinion in rheumatology.
[12] G. Norman,et al. Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.
[13] P. Tugwell,et al. MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. , 2003, The Journal of rheumatology.
[14] Sally C Stearns,et al. Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts? , 2003, Medical care.
[15] D. Redelmeier,et al. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. , 1993, Archives of internal medicine.
[16] J. Kirwan,et al. Minimum clinically important difference: the crock of gold at the end of the rainbow? , 2001, The Journal of rheumatology.
[17] D. A. Cioffi,et al. The American Academy of Orthopaedic Surgeons Outcomes Instruments: Normative Values from the General Population , 2002, The Journal of bone and joint surgery. American volume.
[18] G. Guyatt,et al. The minimal detectable change cannot reliably replace the minimal important difference. , 2010, Journal of clinical epidemiology.
[19] C. Bombardier,et al. Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. , 2001, The Journal of rheumatology.
[20] M. Dougados,et al. Feeling good rather than feeling better matters more to patients. , 2006, Arthritis and rheumatism.
[21] G. Guyatt,et al. Assessing the minimal important difference in symptoms: a comparison of two techniques. , 1996, Journal of clinical epidemiology.
[22] S. van der Linden,et al. Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. , 2001, The Journal of rheumatology.
[23] C. Terwee,et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) after different treatments , 2001, Clinical endocrinology.
[24] C. Naylor,et al. Can there be a more patient-centred approach to determining clinically important effect sizes for randomized treatment trials? , 1994, Journal of clinical epidemiology.
[25] G. Guyatt,et al. Quality of Life Instruments in the Evaluation of New Drugs , 1992, PharmacoEconomics.
[26] G H Guyatt,et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.
[27] C. Bombardier,et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state , 2004, Annals of the rheumatic diseases.
[28] N. Jacobson,et al. Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. , 1999, Journal of consulting and clinical psychology.
[29] A. Wein. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. , 2005, The Journal of urology.
[30] D. Felson,et al. Deriving an operational definition of low disease activity state in rheumatoid arthritis. , 2003, The Journal of rheumatology.
[31] F. Tubach,et al. The variability in minimal clinically important difference and patient acceptable symptomatic state values did not have an impact on treatment effect estimates. , 2009, Journal of clinical epidemiology.
[32] D. Fergusson,et al. Systematic Review of Measures of Clinical Significance Employed in Randomized Controlled Trials of Drugs for Dementia , 2009, Journal of the American Geriatrics Society.
[33] P. Tugwell,et al. MCID/Low Disease Activity State Workshop: summary, recommendations, and research agenda. , 2003, The Journal of rheumatology.
[34] R. Epstein,et al. Interpretation of quality of life changes , 1993, Quality of Life Research.
[35] J. Wright,et al. The minimal important difference: who's to say what is important? , 1996, Journal of clinical epidemiology.
[36] J. Katz,et al. Measuring relevant change: an emerging challenge in rheumatologic clinical trials. , 1995, Arthritis and rheumatism.
[37] R. Hays,et al. Responsiveness and minimal important differences for patient reported outcomes , 2006, Health and quality of life outcomes.
[38] C. Bombardier,et al. Development of an upper extremity outcome measure: The DASH (disabilities of the arm, shoulder, and head) , 1996 .
[39] K. Wyrwich. Minimal Important Difference Thresholds and the Standard Error of Measurement: Is There a Connection? , 2004, Journal of biopharmaceutical statistics.
[40] S. Hogg-Johnson,et al. Three methods for minimally important difference: no relationship was found with the net proportion of patients improving. , 2007, Journal of clinical epidemiology.
[41] G. Guyatt,et al. Interpreting treatment effects in randomised trials , 1998, BMJ.
[42] D. Beaton,et al. Simple as possible? Or too simple? Possible limits to the universality of the one half standard deviation. , 2003, Medical care.
[43] G H Guyatt,et al. Sensitivity to change of the Roland-Morris Back Pain Questionnaire: part 1. , 1998, Physical therapy.
[44] S. Bauer,et al. Clinical Significance Methods: A Comparison of Statistical Techniques , 2004, Journal of personality assessment.
[45] P. V. van Riel,et al. The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.
[46] E. Wise. Methods for Analyzing Psychotherapy Outcomes: A Review of Clinical Significance, Reliable Change, and Recommendations for Future Directions , 2004, Journal of personality assessment.
[47] P. Stratford,et al. Sensitivity to change of the Roland-Morris Back Pain Questionnaire: part 2. , 1998, Physical therapy.
[48] Aileen M. Davis,et al. The DASH (Disabilities of the Arm, Shoulder and Hand) Outcome Measure: What do we know about it now? , 2001 .
[49] C. Bombardier,et al. Measuring the whole or the parts? Validity, reliability, and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. , 2001, Journal of hand therapy : official journal of the American Society of Hand Therapists.
[51] B Shea,et al. Minimal clinically important differences: review of methods. , 2001, The Journal of rheumatology.
[52] P. Stratford,et al. Defining the minimum level of detectable change for the Roland-Morris questionnaire. , 1996, Physical therapy.
[53] Philippe Ravaud,et al. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. , 2005, The Journal of rheumatology.
[54] M. Liang,et al. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. , 2003, Arthritis and rheumatism.
[55] N. Jacobson,et al. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. , 1991, Journal of consulting and clinical psychology.
[56] P Tugwell,et al. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. , 1993, The Journal of rheumatology.
[57] S. Pocock. A perspective on the role of quality-of-life assessment in clinical trials. , 1991, Controlled clinical trials.
[58] D. Cella,et al. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. , 2005, Journal of clinical epidemiology.
[59] W. Tierney,et al. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. , 1999, Journal of clinical epidemiology.